NCT01901120已完成不适用
Long-Term Specified Drug Use-results Survey of Betanis Tablets
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,263
- 主要终点
- Occurrence of adverse events
研究概览
简要总结
This study is to evaluate the safety and efficacy of long-term use of Betanis (generic name: mirabegron), and to determine the adherence to treatment with mirabegron.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who administer mirabegron for treatment of urinary urgency, daytime frequency, and urgency incontinence associated with overactive bladder and also who have no treatment history of mirabegron.
排除标准
- 未提供
研究组 & 干预措施
Betanis
the usual adult dosage of mirabegron once daily after a meal
干预措施: Betanis (Drug)
结局指标
主要结局
Occurrence of adverse events
时间窗: Up to 36 months after treatment
次要结局
- Overactive Bladder Symptom Score (OABSS)(At the start of treatment and 3, 6, 12, 18, 24, 30, and 36 months after treatment)
研究者
相似试验
已完成
不适用
Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney DiseaseChronic Kidney DiseaseNCT02805348Astellas Pharma Inc144
已完成
不适用
Drug Use-Results Survey of Betanis Tablets in JapanOveractive BladderNCT01919047Astellas Pharma Inc10,711
Unknown
早期 1 期
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette SyndromeTourette SyndromeNCT02253498Beijing Pins Medical Co., Ltd20
Unknown
早期 1 期
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Obsessive-Compulsive DisorderObsessive-Compulsive DisorderNCT02253472Beijing Pins Medical Co., Ltd30
已完成
不适用
Specified Drug Use-Results Survey of RegniteRestless Legs SyndromeNCT01887613Astellas Pharma Inc1,597